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Objectives: To estimate long-term CIN3 risks associated with different triage strategies for HPV 
positive women with a view to reducing unnecessary referrals.  
 
Design: The ARTISTIC trial cohort were recruited in Manchester in 2001-03 and were traced for CIN3 
and cancer incidence through national registration until December 2015. 
 
Results: The 10 year cumulative risk of CIN3+ was much higher for women with HPV16/18 infection 
(19.4%, 95%CI:15.8-23.8 with borderline/low-grade cytology and 10.7%, 95%CI:8.3-13.9 with normal 
cytology) than for those with other HPV types (7.3%, 95%CI:5.4-9.7 with borderline/low-grade 
cytology and 3.2%, 95%CI:2.2-4.5 with normal cytology). Among the 379 women with normal to-low-
grade cytology and new HPV infection, the 10 year cumulative CIN3+ risk was 2.9% (95%CI:1.6-5.2). 
  
This article has been accepted for publication and undergone full peer review but has not been through the 
copyediting, typesetting, pagination and proofreading process, which may lead to differences between this 
version and the Version of Record. Please cite this article as doi: 10.1111/1471-0528.1595











Conclusions: The CIN3 risk is confined to women with persistent type-specific HPV so partial 
genotyping test assays identifying HPV16/18 as a minimum are essential for efficient risk 
stratification. Immediate referral to colposcopy for HPV+ women with borderline or low-grade 
cytology and after a year if still HPV+ with normal cytology may be unnecessary. Low grade lesions 
can safely be retested to identify those with persistent HPV. Recall intervals of 1 year for HPV16/18 
and 2 years for high risk HPV are justified for women with normal cytology and might also be 
considered for women with borderline/low-grade cytology. The minimal risk of invasive cancer that 
has progressed beyond stage 1A must be weighed against the advantages for patients and the NHS 
of reducing the number of referrals to colposcopy.   
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Tweetable abstract (<280 chars): Cervical screening would be better for women and cheaper for the 
NHS if women with HPV and normal to low grade cytology were retested after a year or two when 




Primary HPV testing with cytology triage of HPV positive women has been piloted at several sites in 
England following publication of the ARTISTIC Trial results over 3 rounds of HPV screening1-3 and of 
the pooled results with other randomised trials showing a reduction in long-term cervical cancer 
risk.4 (HPV refers throughout to the high-risk human papillomavirus types associated with cervical 
cancer.) The NHS Cervical Screening Programme (NHSCSP) is already one of the most successful in 
the world in preventing cervical cancer,5, 6 and national roll out of primary HPV testing, due to be 
completed by the end of December 2019, should further increase sensitivity. However, colposcopy 
referrals will also increase without more efficient triage methods for HPV positive women. 
Unnecessary referral increases NHS costs and inconvenience to patients7, and over-treatment of 
cervical intraepithelial neoplasia (CIN) can compromise later birth outcomes8. The majority of new 
HPV infections are transient and harmless, and about 70% disappear within a year with slower 
clearance thereafter9. Triage options to identify those whose CIN3+ risk justifies colposcopy referral 
include cytology, HPV genotyping and delayed retesting to identify the minority whose infection has 
persisted10, 11. Molecular triage tests such as viral or host DNA methylation are also being 
evaluated12.  
 
In England, women are invited for screening 3 yearly from age 25 to age 49 then 5 yearly from age 
50 to 64. HPV positive women with borderline or worse cytology are referred to colposcopy13. 
Cytologically normal women who are HPV positive are recalled for annual cytology and HPV testing 
and referred to colposcopy if still HPV positive after 24 months.  
 
The NHSCSP must strike an acceptable balance between cancer risk and the cost and patient 
inconvenience of excessive screening and unnecessary treatment. The current policy of reflex 
cytology for HPV+ samples and immediate colposcopy for high-grade cytology provides effective 
management for these women. Those with high-grade cytology at entry to ARTISTIC included all 10 











prevalent cancers14. The contentious issue is how to triage HPV+ women with low grade or normal 
cytology. Acknowledging that there is no such thing as zero risk, Castle et al15 proposed a triage 
policy based on CIN3 risk in which women are returned to routine screening with less than 2% risk, 
recalled earlier than the routine screening interval with 2-10% risk and referred to immediate 
colposcopy with over 10% risk. We have compared these thresholds with estimated CIN3 risks for 




Women were recruited to the ARTISTIC trial after attending routine cervical screening in Greater 
Manchester and randomly allocated in a ratio of 3:1 to have the HPV result revealed and acted upon, 
or concealed. Liquid based cytology (LBC) samples were collected for cytology and HPV testing, and 
followed for histopathology, between 2001 and 2009. Management of women with abnormal 
cytology was identical in both arms. Women in the revealed arm with normal cytology who tested 
HPV positive were invited for repeat HPV testing at 12 months and if still positive chose between 
immediate colposcopy or repeat HPV testing at 24 months. The study was extended to a third round 
where women on both arms were managed according to national guidelines. HPV testing was 
performed with Hybrid Capture 2 (Qiagen) with a cut-off of RLU/control of 1 pg/µl. Three HPV typing 
assays were used to genotype HC2 positive samples over various periods of the trial. Any high risk 
HPV type detected by any of the assays was included in the analysis2, 3. To recruit adequate numbers 
of older women, the minimum age was increased from 20 to 30 when the recruitment target for 
women aged 20–29 had been reached, then to 40 when there were enough aged 30–39, and so on.1 
 
All participants in the study have been traced through the NHS Central Register mortality and cancer 
registration, including CIN3 to December 2015. The cohort was linked to the NHSCSP call-recall 
database to obtain lifetime cervical screening records, including reasons for ceasing screening 
(usually age or hysterectomy). 
 
No patients were involved in the development of the research. The work was funded by the NIHR-




Women were classified hierarchically into mutually exclusive groups: HPV16 or HPV18, any other 
HPV without HPV16 or HPV18 (i.e. HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 or 68), and HPV negative 
(HC2+ with untyped HPV or HC2 negative). We have shown that the 10 year CIN3+ risk in women 
with normal cytology is higher among those with HPV16 (12.4%, 95%CI:9.3-16.5) than those with 
HPV18 (6.9%, 95%CI:3.8-12.4) but these types were grouped because in the UK 80% of invasive 
cervical cancers are caused by them16. In the ARTISTIC population, HPV16 was about twice as 
common as HPV18. 
 
Infections detected in the first HPV sample taken after entry were classified as new or persistent by 
comparing HPV genotypes with those identified at entry. Women with both new and persistent 
infections were classified as persistent. This analysis was stratified by time from entry to next test, 
which varied by cytology and randomisation arm: those with normal cytology were invited for a 
repeat HPV test after 1 year in the revealed arm, while in the concealed arm they were invited for 
routine follow-up cytology after 3 years. All women with borderline or low-grade cytology were 
invited for repeat cytology after 6 months. 
 
Cumulative CIN3+ risks were estimated by Kaplan-Meier methods modified to allow for interval-
censoring. Cumulative risks were calculated from entry (round 1) and also from round 2 (defined as 











the first HPV test taken 30-48 months after entry).  Women were censored at date of last smear 
prior to hysterectomy except 608 women who were censored at last smear within the trial as they 
were not successfully linked to call-recall data. All analyses were censored on 30 April 2015 to allow 
for late cancer registration. CIN3+ histology was backdated to the beginning of follow-up (round 1 or 
round 2) where the histology/registration occurred within a year of the beginning of follow-up. 
These cases at time zero give an initial step in the K-M curve showing prevalence. Later CIN3+ 
histology/registration dates were backdated to the first test in the preceding year, then further 
backdated to the midpoint of the interval between that test and the preceding test to estimate the 
approximate date when they became screen-detectable. The cumulative risks therefore include 
CIN3s which would be diagnosed if screened at that point in time.. Cervical cancers are shown in 
brackets in the tables by time to cancer registration, including those preceded by CIN3 diagnosis. All 





The analysis includes the 24,496 women who were successfully flagged for cancer incidence and 
mortality. From enrolment to the end of follow-up 482 CIN3 and 23 invasive cervical cancers were 
diagnosed from national registrations or via local histopathology data. Of the 13,591 women who 
had an HPV test at the follow-up round approximately 3 years after entry, 75 were diagnosed with 
CIN3 and 7 with invasive cervical cancer before April 2015. Average follow-up was 12 years.  
 
There were 2,383 HR-HPV+ women with normal, borderline or low-grade cytology at entry (table 1). 
The majority of this triage population had normal cytology (60% in round 1, 71% in round 2), and 
roughly equal proportions of the remainder had borderline or low-grade cytology. The 10 year 
cumulative risk of CIN3+ was much higher with HPV16/HPV18 infection (table 1 and figure 1a: 
19.4%, 95%CI:15.8-23.8 with borderline/low-grade cytology and 10.7%, 95% CI:8.3-13.9 with normal 
cytology) than with other HPV types (7.3%, 95%CI:5.4-9.7 with borderline/low-grade cytology and 
3.2%, 95%CI:2.2-4.5 with normal cytology).  The higher risk at round 1 in ARTISTIC was largely 
accounted for by higher prevalence of high-grade cytology, as the CIN3 risks stratified by cytology 
were similar in both rounds (Table S1). The proportion of HPV positive women who had high grade 
dyskaryosis was 15% aged <45 years and 11% aged 45-64 in round 1, and only 5% aged <45 and 2% 
aged 45-64 in round 2. Among HPV positive women with normal to low-grade cytology figures 1b 
and 1c show little effect of age on cumulative CIN3+ risk below age 45 (p=0.2) but a much lower 10 
year CIN3+ rate (1.6%:4/243) at age 45 or over (p<0.0001 compared to women aged under 45). 
Among women with high grade cytology at entry there was no age difference (cumulative risks of 
55.1% and 53.6% in women aged under and over age 45 respectively, p=0.9). In women who were 
HPV+ at entry the cumulative CIN3 and cervical cancer risks showed opposite effects in relation to 
age. Respective cumulative risks (average follow-up 12 years) for age at entry 20-29, 30-44 and 45-
64 were 16.0% (236/1475), 16.0% (165/1032) and 7.0% (19/273) for CIN3 and 0.2% (3/1475), 1.0% 
(10/1032) and 1.5% (4/273) for cervical cancer. The 10 prevalent invasive cancers were all diagnosed 
within 7 months of entry, and all presented with high-grade cytology. In contrast, only 2 of the 13 
incident cervical cancers diagnosed 4 or more years later had abnormal cytology at entry (1 
borderline, 1 moderate). 
 
Table 2 shows the result of the first HPV test after entry in women who were HPV positive with 
normal to low-grade cytology at entry. The 10 year CIN3+ risk was much lower in women with 
normal cytology at entry who had cleared their initial infection than in those with persisting 
infections. The proportion of women with normal cytology who had cleared their initial infection 
increased from 57% after 1 year to 74% after 3 years and 79% after 5 years, but the proportion 
acquiring new infections also increased (6% at 1 year, 8% at 3 years, 10% at 5 years). The majority of 











those with borderline or low-grade cytology at entry returned for a repeat test after approximately 6 
months, when 32% had cleared their initial infection (10 year CIN3+ risk 2.3% (95%CI:0.9-5.9) 
cleared, 17.7% (95%CI:14.2-21.9) persisting). 
 
HPV16 was more likely to persist than other high risk HPV types. In HPV+ women with normal 
cytology at entry retested at 1 year 55% (74/135) of HPV16 infections persisted compared to 40% 
(196/495) of non-16 infections (p=0.002). Among women with borderline cytology at entry, 80% 
(140/174) of HPV16 infections persisted until the next test 6 months later compared to 63% 
(239/382) of non-16 infections (p<0.001). 
 
CIN3+ risks following round 2 among women who tested HPV negative at entry (table 3) emulate a 
second round of HPV primary screening. The new infection rate was low: 11.9% in women aged 25-
29, 4.6% in women aged 30-39 and 1.6% in women aged 40-64. Among the 387 women with a new 
infection, 70% had normal cytology, 28% had borderline/low-grade cytology and just 2% had high-
grade cytology. Among the 269 women with normal cytology and the 110 women with 
borderline/low-grade cytology, the 10 year CIN3+ risks were 1.5% (95%CI:0.6-3.9) and 6.4% 
(95%CI:3.1-12.9) respectively. Fewer of these infections persisted compared to those detected at 
baseline (shown in table 2): in women with normal cytology, the 12 month persistence rate was 26% 
following a new infection at round 2 compared to 43% from any infection detected at baseline; and 
in women with borderline/low-grade cytology, the 6 month persistence rate was 40% following a 







The convention that a CIN3 risk of about 10% is a reasonable threshold for immediate colposcopy12, 
15 would support the current triage strategies adopted by the NHSCSP (table 4). However partial 
genotyping allows further stratification implying rapid referral only of women with HPV16/18 
infection and borderline/low-grade cytology (5 year risk 18%). These women constitute 16% of the 
HPV+ population who do not have high grade dyskaryosis (table 1, table 4).  Over half of the women 
with borderline/low-grade cytology had non 16/18 HPV infections, of which 40% cleared after 6 
months. The 5 year cumulative risk in those persisting beyond 6 months was 11.0% (95%CI:7.4%-
16.2%) (table 2, table 4). This indicates that the triage protocol for those with borderline/low-grade 
cytology being rolled out in England is too conservative. There would be a 23% reduction in referrals 
if those with non-16/18 HPV types were recalled after 6 months and referred only if persistent, and 
extending the recall interval to 1 year would further reduce the number of referrals. 
 
Women with normal cytology and HPV16/18 infections persisting for 1 year have a substantial CIN3+ 
risk and delaying recall for 1 year reduces referrals by around half (table 4). The cumulative 5 year 
risk in women with non 16/18 infections (2.2%) is near the threshold for routine recall 
recommended by Castle15 so a 2 year delay in recalling them appears justified. A delay in retesting of 
a year for HPV16/18 and 2 years for other HPV types for HPV+ women with normal cytology, was 
adopted by some sites during the pilot but will not continue after the national roll-out. 
 
Reflex cytology provides a good triage strategy for women undergoing their first HPV test as well as 
for previously screened women. However, CIN3+ rates were significantly lower in women with a 
previous negative HPV test (table 3). After the first round of HPV screening the HPV negative 
majority (89% in ARTISTIC) have a 10 year CIN3+ risk of only 0.4%. At the second round of primary 
HPV testing the great majority of HPV+ women who were HPV- at their previous test will have 











normal cytology or the low-grade dyskaryosis associated with a new HPV infection (table 3). Their 10 
year CIN3+ risk is only 1.5% with normal cytology and 6.4% with borderline or low-grade cytology, 
and these women could safely be recalled for repeat testing after at least a year. The HPV positive 
minority at round 1 have a 10 year CIN3+ risk of 14.9%, account for 83% of subsequent CIN3+ cases, 
and remain at much higher risk for invasive cancer beyond 10 years (Table 1: 5/2780 vs. 0/21716 
cancers beyond 10 years, p<0.0001). The continuing clinical burden of repeated HPV testing, 
cytology and colposcopy will thus be largely confined to women who are HPV+ at their first test, 
some of whom will have long-standing precancer missed by previous cytology14.  
 
Strengths and limitations 
 
We have individually linked HPV, screening and cancer registration data for this large cohort with 
almost complete follow-up over 14 years. The cohort included women being screened at age 20-24 
as well as a large number of women aged 40-64. Results at rounds 1 and 2 reflect both the 
introduction of HPV testing and the much lower CIN3 rate at subsequent rounds. The main 
limitations are that the HC2 HPV assay was the only commercially available test in 2001 but is no 
longer used by the NHSCSP, and that colposcopy was rarely done without abnormal cytology and 
biopsies were not taken without atypical colposcopic appearance. Further evidence is needed on 
long-term cancer risks following negative HPV tests using modern assays to determine whether their 







Some of the approved NHSCSP assays can identify genotypes HPV16/18, but triage depends only on 
a positive/negative result. Partial genotyping allowing further stratification is beneficial for two 
reasons. First, the risk of CIN3+ is substantially higher for HPV16/18 than for other HPV types 
irrespective of cytology (table 1). The latter constitute the majority of women, their clearance rates 
are higher and delaying their repeat test will have the greatest impact on the number of colposcopy 
referrals. The second advantage is that persistent HPV16 or HPV18 infections can be distinguished 
from new infections. As the recall interval increases, so does the proportion of double positive 
infections which are in fact one infection clearing followed by new infection. Such type swaps 
occurred in 12% (37/307) of women with normal cytology after 1 year, 22% (22/98) after 3 years and 
31% (14/45) at 5 years (table 2). The 5-year CIN3 risk for those with type-specific persistence is 4-5 
times greater than for those with new infections, whose risk is independent of previous HPV 
infection that has disappeared14.  
 
Implications of delayed recall 
 
Screening policy is inevitably based on CIN3 diagnosis because of the extreme rarity of invasive 
cancer in screened women. The primary aim of screening is to prevent cancer by detecting and 
treating CIN3, but a major additional benefit is early cancer diagnosis. Most cervical cancers in 
regularly screened women are diagnosed at FIGO stage 16. The virtual absence of cancer in women 
aged under 20 despite the large number of HPV infections from age 14 to 1917 suggests that a delay 
of 6-12 months in diagnosing CIN3 will not cause a detectable increase in cancer risk. Prevalent 
cancers, including all 10 in ARTISTIC, almost always present with high grade cytology. In 8,056 
colposcopy referrals during the first round of the UK pilot, invasive cancer was diagnosed in two 
(0.035%) women following borderline/low-grade cytology and 56 (2.35%) following high-grade 
cytology18. This indicates that CIN3 is usually incipient following borderline/low-grade cytology but is 











often prevalent in women with high-grade cytology. The respective CIN3 and cancer risks beyond 2.5 
years from entry to ARTISTIC were 3.3% (47/1407) and 0.4% (6/1407) in HPV+ women with normal 
cytology and 2.7% (23/852) and 0.1% (1/852) in HPV+ women with borderline/low-grade cytology at 
entry (table 1). A delay in retesting of a year for HPV16/18 and 2 years for other HPV types, might 
therefore be considered for borderline/low-grade cytology. This would delay CIN3 diagnosis but will 
rarely delay cancer diagnosis. The minimal increase in the risk of developing cancer was accepted 
before HPV testing was introduced as a triage test for primary cytology screening around 10 years 
ago, and it is not clear that this risk/benefit balance should be abandoned for non 16/18 HPV 
infection with low-grade cytology, which is the normal manifestation of an active HPV infection, 




Part of the continuing long-term increase in cumulative incidence of CIN3+ in HPV+ women with 
normal cytology (figure 1a) is due to occult CIN3 undetected by cytology. In a prospective study in 
the Netherlands 6 of the 8 women with untreated CIN who regressed to normal cytology and 
colposcopy but remained HPV positive over several years had occult CIN3 detected by random 
biopsy20. Current colposcopy guidelines21 do not recommend taking biopsies from women with 
normal, borderline or low-grade cytology without an atypical transformation zone. This was based 
on the 8% CIN2+ risk in women attending colposcopy but not eligible for biopsy whose HPV status 
was not known22, which must be an underestimate for persistently HPV+ women. HPV+ women with 
normal cytology in the revealed arm of ARTISTIC were offered colposcopy if they were still HC2+ a 
year later. Among the 169 women who attended colposcopy, only half (81) of whom were biopsied, 
9 CIN3s (5.3%) were diagnosed immediately and 15 CIN3s were diagnosed after further biopsies, a 
cumulative CIN3+ risk of 14.2%. It is not known how many more would have been diagnosed with 
random biopsy. A US trial reported an 8.5% prevalence of CIN3 in women with normal cytology 
referred to colposcopy and biopsy (directed or random) after a single positive test for HPV 16/18.23 
Women with HPV infection and normal cytology form the majority of the triage population, and 
there is an urgent need for better evidence to inform colposcopy management guidelines for these 
women. 
 
Triage in older women 
 
Among women aged <45 who were HPV+ at entry the long-term CIN3 risk (16.0%) was unrelated to 
age but was lower (7.0%) in HPV+ women aged ≥45. These findings are similar to those reported 
from the UK pilot (4.8% in HPV+ women aged ≥50 vs 9.1% in HPV+ women aged 30-49)13. This 
reduction could be due to physical difficulties in collecting adequate pathology24 or under-diagnosis 
of occult CIN320 in older women. Invasive cervical cancer risk increased from 0.2% at age 20-29 to 
1.0% at 30-44 and 1.5% above age 45 so a longer delay before retesting would not be safe. 
Irrespective of cytology post-menopausal women with persistent HPV might choose therapeutic 





Immediate referral of all HPV+ women with borderline or low-grade cytology as recommended for 
the roll-out of primary HPV screening will not be cost-effective, particularly in women who have 
tested HPV negative in the previous round of screening. We suggest that low grade lesions can safely 
be retested to identify those with persistent HPV. Recall intervals of 1 year for HPV 16/18 and 2 
years for the remainder have been piloted in some regions for women with normal cytology and 
might also be considered for women with borderline/low-grade cytology. The risk is confined to 











women with a persisting type-specific HPV so partial genotyping test assays identifying HPV 16/18 as 
a minimum provide more efficient risk stratification. The minimal risk of invasive cancer that has 
progressed beyond stage 1A must be weighed against the advantages for patients and the NHS of 
reducing the number of referrals to colposcopy.   
 
The major unresolved issue which will become increasing important is management of women with 
persistent HPV infection and normal cytology after two rounds of triage. A study should be 
conducted to evaluate whether random biopsy (or LEEP in post-menopausal women) is substantially 
more sensitive than colposcopically directed biopsy for diagnosing disease in women with type-
specific HPV persistence and normal or low grade cytology. This could reduce the number of repeat 





Ethical approval: Ethical approval of the study was obtained from South East Coast NRES Committee 
(14/LO/0627) on 13/05/2014 and Section 251 support to process confidential patient information 
without consent was given by UK Health Research Authority Confidentiality Advisory Group.  
 
Availability of data: No additional data are available, in compliance with ethical and governance 
regulations under which this research was undertaken. 
 
Conflicts of interest: CG received speaker fees from Roche paid to employer and a grant from NIHR-
HTA to fund this project. AS attended meetings with HPV assay manufacturers; speaker fees from 
Roche; travel and accommodation from Roche and Abbott for training and user group meetings; 
Roche, Abbott, Hologic, Becton Dickinson and Cepheid provided kits for assay validation purposes; 
PHE provided funding to support the NHS screening laboratory activity for the pilot.  JP received a 
grant from NIHR-HTA to fund this project. 
Completed disclosure of interest forms are available to view online as supporting information. 
 
Funding: The work was funded by the NIHR-HTA and Cancer Research UK.  
 
Authorship: CG conducted all statistical analysis and drafted the report. AS conducted all HPV testing 
for the ARTISTIC trial. JP was the epidemiological PI of the ARTISTIC trial and contributed to the 
design of the trial, initiated the follow-up study, contributed to the statistical analysis and writing of 
the report. 
  













1. Kitchener HC, Almonte M, Gilham C, Dowie R, Stoykova B, Sargent A, et al. ARTISTIC: a 
randomised trial of human papillomavirus (HPV) testing in primary cervical screening. Health Technol 
Assess. 2009 Nov;13(51):1-150, iii-iv 
2. Kitchener HC, Gilham C, Sargent A, Bailey A, Albrow R, Roberts C, et al. A comparison of HPV 
DNA testing and liquid based cytology over three rounds of primary cervical screening: extended 
follow up in the ARTISTIC trial. Eur J Cancer. 2011 Apr;47(6):864-71 
3. Kitchener H, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, et al. The clinical 
effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: 
extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds. Health 
Technol Assess. 2014 Apr;18(23):1-196 
4. Ronco G, Dillner J, Elfstrom KM, Tunesi S, Snijders PJ, Arbyn M, et al. Efficacy of HPV-based 
screening for prevention of invasive cervical cancer: follow-up of four European randomised 
controlled trials. Lancet. 2014 Feb 08;383(9916):524-32 
5. Peto J, Gilham C, Fletcher O, Matthews FE. The cervical cancer epidemic that screening has 
prevented in the UK. Lancet. 2004 Jul 17-23;364(9430):249-56 
6. Landy R, Pesola F, Castanon A, Sasieni P. Impact of cervical screening on cervical cancer 
mortality: estimation using stage-specific results from a nested case-control study. Br J Cancer. 2016 
Oct 25;115(9):1140-6 
7. Landy R, Birke H, Castanon A, Sasieni P. Benefits and harms of cervical screening from age 20 
years compared with screening from age 25 years. Br J Cancer. 2014 Apr 2;110(7):1841-6 
8. Castanon A, Brocklehurst P, Evans H, Peebles D, Singh N, Walker P, et al. Risk of preterm 
birth after treatment for cervical intraepithelial neoplasia among women attending colposcopy in 
England: retrospective-prospective cohort study. BMJ. 2012 Aug 16;345:e5174 
9. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, Rozendaal L, Remmink AJ, Risse EK, et al. 
Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer 
screening: a prospective study. Lancet. 1999 Jul 03;354(9172):20-5 
10. Kjaer SK, Frederiksen K, Munk C, Iftner T. Long-term absolute risk of cervical intraepithelial 
neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl 
Cancer Inst. 2010 Oct 06;102(19):1478-88 
11. Castle PE, Rodriguez AC, Burk RD, Herrero R, Wacholder S, Alfaro M, et al. Short term 
persistence of human papillomavirus and risk of cervical precancer and cancer: population based 
cohort study. BMJ. 2009 Jul 28;339:b2569 
12. Wentzensen N, Schiffman M, Palmer T, Arbyn M. Triage of HPV positive women in cervical 
cancer screening. J Clin Virol. 2016 Mar;76 Suppl 1:S49-55 
13. Rebolj M, Rimmer J, Denton K, Tidy J, Mathews C, Ellis K, et al. Primary cervical screening 
with high risk human papillomavirus testing: observational study. BMJ. 2019 Feb 6;364:l240 
14. Gilham C, Sargent A, Kitchener HC, Peto J. HPV testing compared with routine cytology in 
cervical screening: long-term follow-up of ARTISTIC RCT. Health Technol Assess. 2019 Jun;23(28):1-
44 
15. Castle PE, Sideri M, Jeronimo J, Solomon D, Schiffman M. Risk assessment to guide the 
prevention of cervical cancer. Am J Obstet Gynecol. 2007 Oct;197(4):356 e1-6 
16. Mesher D, Cuschieri K, Hibbitts S, Jamison J, Sargent A, Pollock KG, et al. Type-specific HPV 
prevalence in invasive cervical cancer in the UK prior to national HPV immunisation programme: 
baseline for monitoring the effects of immunisation. J Clin Pathol. 2015 Feb;68(2):135-40 
17. Jit M, Vyse A, Borrow R, Pebody R, Soldan K, Miller E. Prevalence of human papillomavirus 
antibodies in young female subjects in England. Br J Cancer. 2007 Oct 8;97(7):989-91 
18. Moss S, Gibney A. HPV Primary Screening Pilots: Evaluation report to the National Screening 
Committee 2015 [cited 2019 14 Feb 2019]. Available from: 
https://legacyscreening.phe.org.uk/policydb_download.php?doc=560. 











19. Moscicki AB, Shiboski S, Hills NK, Powell KJ, Jay N, Hanson EN, et al. Regression of low-grade 
squamous intra-epithelial lesions in young women. Lancet. 2004 Nov 6-12;364(9446):1678-83 
20. Nobbenhuis MA, Helmerhorst TJ, van den Brule AJ, Rozendaal L, Voorhorst FJ, Bezemer PD, 
et al. Cytological regression and clearance of high-risk human papillomavirus in women with an 
abnormal cervical smear. Lancet. 2001 Nov 24;358(9295):1782-3 
21. PHE. Colposcopy and programme management guidelines for the NHS cervical screening 
programme 2016. 
22. Howells RE, O'Mahony F, Tucker H, Millinship J, Jones PW, Redman CW. How can the 
incidence of negative specimens resulting from large loop excision of the cervical transformation 
zone (LLETZ) be reduced? An analysis of negative LLETZ specimens and development of a predictive 
model. BJOG. 2000 Sep;107(9):1075-82 
23. Stoler MH, Wright TC, Jr., Parvu V, Yanson K, Cooper CK, Andrews J. Stratified risk of high-
grade cervical disease using onclarity HPV extended genotyping in women, >/=25years of age, with 
NILM cytology. Gynecol Oncol. 2019 Apr;153(1):26-33 
24. Gravitt PE, Landy R, Schiffman M. How confident can we be in the current guidelines for 
exiting cervical screening? Prev Med. 2018 Sep;114:188-92 
 
  











Table 1 – Cumulative CIN3+ risks from entry by HPV partial genotype and cytology. Invasive cervical cancers (ICC) are also shown in brackets. 
Follow-up from entry 
HPV/cytology at entry  To Dec 
20152 
2.5 year risk from entry 5 year risk from entry 10 year risk from entry 






% 95% CI n CIN3+ 
(ICC) 
% 95% CI n CIN3+ 
(ICC) 
% 95% CI 
HR-HPV negative3 21716 (88.7%) 86 (6)4 29 (1) 0.13% (0.09%, 0.19%) 50 (2) 0.23% (0.18%, 0.30%) 80 (6) 0.37% (0.30%, 0.47%) 
HR-HPV positive 2780 (11.3%) 419 (17) 337 (9) 12.1% (11.0%, 13.4%) 385 (9) 13.9% (12.6%, 15.2%) 413 (12) 14.9% (13.6%, 16.3%) 
Normal cytology            
HPV16/HPV18 478 (17.2%) 51 (2) 23 4.8% (3.2%, 7.2%) 42 8.8% (6.6%, 11.7%) 51  10.7% (8.3%, 13.9%) 
Other HR-HPV 961 (34.6%) 34 (4) 9 0.9% (0.5%, 1.8%) 21 (2) 2.2% (1.4%, 3.4%) 30 (2) 3.2% (2.2%, 4.5%) 




         
HPV16/HPV18 376 (13.5%) 75 (1) 61 16.2% (12.9%, 20.4%) 69 18.4% (14.8%, 22.7%) 73 19.4% (15.8%, 23.8%) 
Other HR-HPV 568 (20.4%) 41 31 5.5% (3.9%, 7.7%) 38 6.7% (4.9%, 9.1%) 41 7.3% (5.4%, 9.7%) 
All HR-HPV+ 944 (34.0%) 116 (1) 92 9.8% (8.0%, 11.8%) 107 11.4% (9.5%, 13.6%) 114 12.1% (10.2%, 14.4%) 
Moderate/severe cytology            
HPV16/HPV18 250 (9.0%) 159 (5) 158 (4) 63.2% (57.3%, 69.2%) 159 (4) 63.6% (57.7%, 69.5%) 159 (5) 63.6% (57.7%, 69.5%) 
Other HR-HPV 147 (5.3%) 59 (4) 55 (4) 37.4% (30.2%, 45.8%) 56 (4) 38.1% (30.8%, 46.5%) 59 (4) 40.2% (32.8%, 48.6%) 
All HR-HPV+ 397 (14.3%) 218 (10)5 213 (9)5 53.7% (48.8%, 58.6%) 215 (9)5 54.2% (49.4%, 59.1%) 218 (10)5 54.9% (50.1%, 59.9%) 
All women from entry 24496 505 (23) 366 (10)   435 (11)   493 (18)   
1 percentages by cytology are given out of 2780 total HR-HPV+ women 
2In 12 to 14 years of follow-up 
3HC2 negative or HC2 positive with no HR-HPV detected. 
4 One invasive cancer diagnosed 4 months after entry and 4 cancers diagnosed more than 2.5 years after entry tested HC2 negative, but HR-HPV was 
detected on later retesting of the entry sample by PCR, so 5 of the 6 cancers shown as HR-HPV negative might have been HPV positive with a modern HPV 
assay.14 
5 One invasive cancer diagnosed 4 months after severe cytology at entry which tested HC2 positive with insufficient sample for typing is shown in the table 
as HR-HPV+ 
  











Table 2 – Cumulative CIN3+ risks following next HPV test in women who were HR-HPV positive with normal, borderline or low-grade cytology at entry. 
Invasive cervical cancer (ICC) cases are also shown in brackets. 
 
   2.5 year risk from next test 5 year risk from next test 10 year risk from next test 
Median time to next HPV test  
and HPV status 




% 95% CI n CIN3+ 
(ICC) 
% 95% CI n CIN3+ 
(ICC) 
% 95% CI 
Normal cytology2            
1 year1            
   HPV cleared 323 (51.4%) 73 3 0.9% (0.3%, 2.9%) 4 1.2% (0.5%, 3.3%) 7 2.2% (1.1%, 4.6%) 
   HPV new infection 37 (5.9%) 0 0 0%  0 0%  0 0%  
   HPV persisting 269 (42.8%) 37 (2) 25  9.3% (6.4%, 13.4%) 32(1) 11.9% (8.6%, 16.4%) 37(2) 13.8% (10.2%, 18.5%) 
HPV 16/18 persisting 103 (52.3%) 25 (1) 18 17.5% (11.4%, 26.3%) 23 22.3% (15.4%, 31.7%) 25 (1) 24.3% (17.1%, 33.8%) 
Other HRHPV persisting 166 (38.4%) 12 (1) 7 4.2% (2.0%, 8.6%) 9 (1) 5.4% (2.9%, 10.2%) 12 (1) 7.3% (4.2%, 12.4%) 
3 years1            
   HPV cleared 193 (66.3%) 14 1 0.5% (0.1%, 3.6%) 1 0.5% (0.07%, 3.6%) 1 0.5% (0.07%, 3.6%) 
   HPV new infection 22 (7.6%) 1 0 0%  0 0%  1 4.6% (0.7%, 28.1%) 
   HPV persisting 76 (26.1%) 17 (2) 14 (1) 18.4% (11.4%, 29.1%) 15 (1) 19.7% (12.4%, 30.6%) 17 (2) 22.4% (14.6%, 33.5%) 
HPV 16/18 persisting 31 (27.9%) 6 6 19.4% (9.2%, 38.1%) 6 19.4% (9.2%, 38.1%) 6 19.4% (9.2%, 38.1%) 
Other HRHPV persisting 45 (25.0%) 11 (2) 8 (1) 17.8% (9.3%, 32.4%) 9 (1) 20.0% (11.0%, 34.9%) 11 (2) 24.4% (14.4%, 39.8%) 
5 years1            
   HPV cleared 101 (69.2%) 15 1 1.0% (0.1%, 6.8%) 1 1.0% (0.1%, 6.8%)    
   HPV new infection 14 (9.6%) 1 1 7.1% (1.0%, 40.9%) 1 7.1% (1.0%, 40.9%)    
   HPV persisting 31 (21.2%) 11 9 29.0% (16.3%, 48.4%) 11 35.5% (21.5%, 54.9%)    
HPV 16/18 persisting 20 (32.8%) 9 8 40.0% (22.4%, 64.3%) 9 45.0% (26.5%, 68.7%)    
Other HRHPV persisting 11 (12.9%) 2 1 9.1% (1.3%, 49.2%) 2 18.2% (4.9%, 55.3%)    
Borderline/low-grade cytology6            
6 months1            
   HPV cleared 153 (27.5%) 4 3 2.0% (0.6%, 6.0%) 4 2.6% (1.0%, 6.8%) 4 2.6% (1.0%, 6.8%) 
   HPV new infection 24 (4.3%) 0 0   0   0   
   HPV persisting 379 (68.2%) 67 59 15.6% (12.3%, 19.6%) 65 17.2% (13.7%, 21.3%) 67 17.7% (14.2%, 21.9%) 
HPV 16/18 persisting 178 (78.8%) 45 39 21.9% (16.5%, 28.7%) 43 24.2% (18.5%, 31.2%) 45 25.3% (19.6%, 21.4%) 
Other HRHPV persisting 201 (60.9%) 22 20 10.0% (6.5%, 15.0%) 22 11.0% (7.4%, 16.2%) 22 11.0% (7.4%, 16.2%) 
 
1 Median follow up times are shown, the time range for each are for normal cytology: 1.13 years (<2 years), 3.12 years (2-4 years), 5.19 years (≥4  years) and 
6.4 months (<2 years) for borderline or low-grade cytology. 











2317 women with cytology and no HPV at follow-up (9 CIN3+) and 56 women with no follow-up recorded (no CIN3+) are excluded 
3 1 had same type after a negative HPV test, 2 cleared and were infected with new HR HPV types and 4 had no subsequent HPV tests prior to diagnosis 
(sometimes several years later) 
4 HR-HPV NK as sample insufficient for typing 
5 Assumed cleared (HC2 neg) but same type at diagnosis as at entry 
6 350 with cytology and no HPV at follow-up (39 CIN3+), 27 women with no follow-up within 2 years (6 CIN3+) and 11 women with no follow-up recorded 
(no CIN3+) are excluded  
 
  











Table 3 – Cumulative CIN3+ risks following round 2 in women who tested HR-HPV negative3 at entry. Invasive cervical cancer (ICC) cases are also shown 
in brackets. 
 
HPV and cytology test result 
at round 2 in women who 
tested HR-HPV negative at 
baseline 
  2.5 year risk from round 2 5 year risk from round 2 10 year risk from round 2 







% 95% CI n 
CIN3+ 
(ICC) 
% 95% CI n 
CIN3+ 
(ICC) 
% 95% CI 
HR-HPV negative3 11,945 (96.9%) 16 (2) 8  0.07% (0.03%, 0.13%) 11 (1) 0.09% (0.05%, 0.17%) 16 (2) 0.14% (0.08%, 0.22%) 
HR-HPV positive 387 (3.1%) 14 (1)4 13 (1) 3.4% (2.0%, 5.7%) 14 (1) 3.6% (2.2%, 6.0%) 14 (1) 3.6% (2.2%, 6.0%) 
Normal cytology            
HPV16/HPV18 75 (19.4%) 2 (1)4 1 (1) 1.3% (0.2%, 9.1%) 2 (1) 2.7% (0.7%, 10.2%) 2 (1) 2.7% (0.7%, 10.2%) 
Other HR-HPV 194 (50.1%) 2 2 1.0% (0.3%, 4.1%) 2 1.0% (0.3%, 4.1%) 2 1.0% (0.3%, 4.1%) 
All HR-HPV+ 269 (69.5%) 4 3 1.1% (0.4%, 3.4%) 4 1.5% (0.6%, 3.9%) 4 1.5% (0.6%, 3.9%) 
Borderline/low-grade 
cytology 
           
HPV16/HPV18 49 (12.7%) 4  4 8.2% (3.1%, 20.3%) 4 8.2% (3.1%, 20.3%) 4 8.2% (3.1%, 20.3%) 
Other HR-HPV 61 (15.8%) 3 3 4.9% (1.6%, 14.5%) 3 4.9% (1.6%, 14.5%) 3 4.9% (1.6%, 14.5%) 
All HR-HPV+ 110 (28.4%) 7 7 6.4% (3.1%, 12.9%) 7 6.4% (3.1%, 12.9%) 7 6.4% (3.1%, 12.9%) 
Moderate/Severe cytology            
HPV16/HPV18 4 (1.0%) 1 1 25.0% (4.0%, 87.2%) 1 25.0% (4.0%, 87.2%) 1 25.0% (4.0%, 87.2%) 
Other HR-HPV 4 (1.0%) 2 2 50.0% (15.5%, 94.2%) 2 50.0% (15.5%, 94.2%) 2 50.0% (15.5%, 94.2%) 
All HR-HPV+ 8 (2.1%) 3 3 37.5% (13.9%, 77.1%) 3 37.5% (13.9%, 77.1%) 3 37.5% (13.9%, 77.1%) 
Total women 12,3325 30 (3) 21 (1)   25 (2)   30 (3)   
1 percentages by cytology are given out of 387 HR-HPV+ women 
2In 12 years of follow-up 
3HC2 negative or HC2 positive with no HR-HPV detected 
4 HPV16 was detected at round 2 in this prevalent invasive cancer. This woman tested HC2 negative at entry but HPV16 was detected on later retesting of 
the entry sample by PCR, so it might have been HPV positive with a modern HPV assay.14 
554 women with no cytology taken at round 2 are excluded from the table 
  












 Table 4 – Clinical outcomes of different triage strategies of HR-HPV positive women by cytology and HPV genotype 
Strata Action Estimated proportion of 
referrals % (n)1 
5 year cumulative CIN3 risk 
Current policy:    
Normal cytology  





 Repeat 12 months, repeat 12 months if still HPV positive2 49% (306/629) 10.5% (7.5%, 14.5%) 
 Repeat 24 months, referral if still HPV positive 33% (97/290)3 15.5% (9.6%, 24.3%) 





11.4% (9.5%, 13.6%) 
Alternative strategies:    
Normal HPV16/18     
(n=478, 20%) Immediate referral 100% 8.8% (6.6%, 11.7%)  
 Repeat 12 months, referral if persistent 52% (103/197) 22.3% (15.4%, 31.7%) 
 Repeat 36 months,  referral if persistent 28% (31/111) 19.4% (9.2%, 38.1%) 
Normal Other HR-HPV     
(n= 961, 40%) Immediate referral 100% 2.2% (1.4%, 3.4%) 
 Repeat 12 months,  referral if persistent 38% (166/432) 5.4% (2.9%, 10.2%) 
 Repeat 36 months,  referral if persistent 25% (45/180) 20.0% (11.0%, 34.9%) 
Borderline/ low-grade HPV16/18     
(n=376, 16%) Immediate referral 100% 18.4% (14.8%, 22.7%) 
 Repeat 6 months,  referral if persistent 79% (178/226) 24.2% (18.5%, 31.2%) 
Borderline/low-grade Other HR-HPV     
(n=568, 24%) Immediate referral 100% 6.7% (4.9%, 9.1%) 
 Repeat 6 months,  referral if persistent 61% (201/330) 11.0% (7.4%, 16.2%) 
1 n gives the number used to calculate the estimated proportion of referrals 
2 and normal cytology 
3 based on average 36 month recall interval (24-48 months) 
 
















Figure 1a – Cumulative CIN3+ risk by HPV type and cytology  












Figure 1b – Cumulative CIN3+ risk by age and HPV type in women with normal cytology at entry 












Figure 1c – Cumulative CIN3+ risk by age and HPV type in women with borderline/low-grade 
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